Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

How to know when a re-biopsy is necessary for an advanced NSCLC patient?

In non-squamous advanced NSCLC, 5 biomarkers should be tested in the initial biopsy to base the first line treatment decision: EGFR, ALK, ROS-1, BRAF and PD-L1.

When it hasn't been done at baseline, Solange Peters says it is still important to search for these biomarkers to make a treatment decision after progression.

When an initial biopsy results are available, at progression it is not mandatory to re-test. However, in case more targeted therapies are available at the clinic or for clinical research purposes if rare mutations are found, the second biopsy may give valuable information to decide on a second or third line treatment, especially when an oncogenic driver has been identified at baseline.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.